Anti Cd 20 Ocrevus denied as experimental or investigational by Cigna?

Cigna's specific coverage criteria for anti cd20 ocrevus are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna May Label Ocrelizumab "Experimental"

Ocrelizumab (Ocrevus) has received FDA approval for both relapsing forms of multiple sclerosis and primary progressive multiple sclerosis. A Cigna denial categorizing it as "experimental" or "investigational" therefore warrants careful scrutiny. These denials typically arise in one of three situations: (1) the requested use is for a subtype or indication not listed in the FDA-approved label or in Cigna's coverage criteria; (2) the denial was generated in error due to a coding mismatch; or (3) Cigna's coverage policy has not yet been updated to reflect a relatively recent approval or an updated guideline. In all cases, the denial is contestable.

## Why This Denial Is Appealable

An experimental/investigational denial is an adverse benefit determination subject to your full appeal rights. Under ACA §2719 and ERISA §503 you are entitled to a full-and-fair internal appeal and, if upheld, independent external review by a certified IRO. Crucially, external IROs reviewing experimental-use denials apply a different standard — they must evaluate whether the requested use is supported by clinical evidence and recognized by medical specialty organizations, not merely whether Cigna's internal criteria are met. The external-review window is generally around four months from the adverse determination; verify your deadline. Expedited review is available when delay poses a serious health risk.

## Your Appeal Timeline

1. Request the denial letter and Cigna's coverage policy — identify the specific provision under which the experimental label was applied. 2. Confirm the FDA-approved indication matches the patient's documented diagnosis and the coded indication on the claim. 3. File the internal appeal with FDA approval documentation and clinical-society position statements. 4. Escalate to external review if denied internally — IROs are well-positioned to overturn experimental denials for FDA-approved drugs used on-label.

## Documentation to Gather

• FDA prescribing label for ocrelizumab: the label is publicly available and explicitly lists the approved MS indications. Attach a current copy.
• Diagnosis confirmation: neurology notes, MRI reports, and any subspecialty records establishing the patient's MS subtype as an on-label indication.
• Clinical-society support: a reference (not statistics) to the relevant neurology guideline organization — such as the AAN or comparable body — that includes ocrelizumab in its treatment recommendations for the patient's MS type.
• Cigna's own prior-authorization history: if Cigna previously authorized ocrelizumab for this patient, include that authorization, as it undermines a current experimental classification.
• Prescriber letter: the neurologist should affirm that the prescribed use is FDA-approved, consistent with recognized specialty guidelines, and medically necessary for this specific patient.

## Criteria-Mapping Structure

Obtain Cigna's experimental/investigational coverage policy and map the patient's situation against each criterion Cigna uses to determine "established" versus "experimental" status:

| Cigna Experimental Criterion | Patient's Situation | Supporting Document | |---|---|---| | FDA approval for indication | Approved for [patient's MS type] | FDA label (attached) | | Recognition by specialty societies | AAN guideline includes ocrelizumab | Guideline citation | | Consistent with accepted clinical practice | Prescribed by board-certified neurologist | Prescriber letter |

Because FDA approval is a matter of public record, a well-documented appeal that leads with the label and guideline support has a strong foundation for both internal reconsideration and external review.